Search results
Results from the WOW.Com Content Network
2-Oxazolidinone is a heterocyclic organic compound containing both nitrogen and oxygen in a 5-membered ring. ... -3-phenylurea upon treatment with aniline ...
In pharmacokinetics, a loading dose is an initial higher dose of a drug that may be given at the beginning of a course of treatment before dropping down to a lower maintenance dose. [ 1 ] A loading dose is most useful for drugs that are eliminated from the body relatively slowly, i.e. have a long systemic half-life .
Trimethadione (Tridione) is an oxazolidinedione anticonvulsant.It is most commonly used to treat epileptic conditions that are resistant to other treatments.. It is primarily effective in treating absence seizures, but can also be used in refractory temporal lobe epilepsy.
Oxazolidine is a five-membered heterocycle ringwith the formula (CH 2) 3 (NH)O.The O atom and NH groups are not mutually bonded, in contrast to isoxazolidine. [ 2 ] [ 3 ] Oxazolidines (emphasis on plural) are derivatives of the parent oxazolidine owing to the presence of substituents on carbon and/or nitrogen.
2‑oxazoline, 3‑oxazoline, and 4‑oxazoline (from left to right) Three structural isomers of oxazoline are possible depending on the location of the double bond, however only 2‑oxazolines are common. 4‑Oxazolines are formed as intermediates during the production of certain azomethine ylides [2] but are otherwise rare. 3‑Oxazolines are even less common but have been synthesised ...
Some patients request to be switched to a different narcotic due to stigma associated with a particular drug (e.g. a patient refusing methadone due to its association with opioid addiction treatment). [4] Equianalgesic charts are also used when calculating an equivalent dosage of the same drug, but with a different route of administration.
The oxazolidones and isoxazolidones are a set of six isomeric five-membered heterocyclic compounds consisting of a carbonyl group, an oxygen atom, a nitrogen atom with a hydrogen atom attached, and two methylene groups.
The lack of superiority over existing treatment, combined with lacking placebo-controlled trials, means that few modern drugs have earned FDA approval as initial monotherapy. In contrast, Europe only requires equivalence to existing treatments and has approved many more.